Latest Content

CURE was live on site at the the 19th Annual New York GU Cancers Congress®, where we spoke with Dr. Ulka Vaishampayan on the topic of kidney cancer.

Dr. Anastasia Tousimis explores the feasibility, risks and surgical techniques for performing NSM in radiated patients to ensure oncologic safety.

That’s what I need to remember: Not made-up scenarios, but that if I’m open, truly open, to whatever life has in store, it will be OK.

Keytruda plus weekly paclitaxel improved overall and progression-free survival in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

A study of 922 patients shows the Aida test predicts 10-year recurrence risk and helps guide radiation decisions for invasive breast cancer.

A structured exercise program may reduce cognitive decline, often referred to as “chemo brain,” in patients receiving chemotherapy for the first time.

Dr. Ajay K. Nooka, highlights how the evolution of therapy has moved the goalposts from simply achieving remission to pursuing a measurable cure.

Dr. Sandeep Kunwar explained that getting drugs into the brain is a major hurdle for glioblastoma, as the blood-brain barrier blocks most treatments.

After losing her eyelashes during chemotherapy, a two-time cancer survivor reflects on how their return reshaped her appreciation for a small but meaningful part of daily life.

Preliminary INVINCIBLE-4 study data shows INT230-6 plus standard care may increase pathological complete response rates and improve patient safety.

Dr. Matthew Galsky discusses the background of the KEYNOTE-B15 study, the key results and what these findings could mean for patients.

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves survival in platinum-resistant ovarian cancer.